NASDAQ:TRVI Trevi Therapeutics (TRVI) Stock Price, News & Analysis $17.26 0.00 (0.00%) Closing price 09/4/2026 04:00 PM EasternExtended Trading$17.24 -0.02 (-0.12%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Trevi Therapeutics Stock (NASDAQ:TRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Trevi Therapeutics alerts:Sign Up Key Stats Today's Range$16.80▼$17.3250-Day Range$16.52▼$19.5052-Week Range$6.93▼$20.22Volume856,670 shsAverage Volume1.41 million shsMarket Capitalization$2.46 billionP/E RatioN/ADividend YieldN/APrice Target$27.08Consensus RatingBuy Company Overview Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions. Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy. In addition to its TTX program, Trevi maintains a pipeline of preclinical and discovery-stage assets aimed at broadening treatment options for patients with refractory pain syndromes. Headquartered in San Diego, California, Trevi Therapeutics conducts research and development activities at its U.S. facilities and collaborates with academic institutions and contract research organizations to advance its clinical candidates. The company’s leadership team combines expertise in pharmaceutical development, regulatory affairs and commercialization strategy to guide its growth as a specialty biopharmaceutical innovator.AI Generated. May Contain Errors. Read More Trevi Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreTRVI MarketRank™: Trevi Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 269th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTrevi Therapeutics has a consensus price target of $27.08, representing about 56.9% upside from its current price of $17.26.Amount of Analyst CoverageTrevi Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Trevi Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.48) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -50.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -50.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 12.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Trevi Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.50% of the float of Trevi Therapeutics has been sold short.Short Interest Ratio / Days to CoverTrevi Therapeutics has a short interest ratio ("days to cover") of 7.83.Change versus previous monthShort interest in Trevi Therapeutics has recently decreased by 3.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.03 News SentimentTrevi Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Trevi Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for TRVI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.39% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Trevi Therapeutics' insider trading history. Receive TRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRVI Stock News HeadlinesRaymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)September 5 at 7:40 AM | theglobeandmail.comTrevi Therapeutics (TRVI) Receives a New Rating from B. Riley SecuritiesSeptember 5 at 7:40 AM | theglobeandmail.comForget SpaceX, Elon Is Now Powering the Next Hot IPOElon Musk is backing a new AI startup that's quietly growing faster than Tesla, SpaceX, and reportedly 23 times faster than Nvidia, according to Jeff Brown of Brownstone Research. The company recently filed paperwork for what could become the next major IPO on Wall Street. Investors can explore how to claim a pre-IPO stake for as little as $50 before shares go public.September 8 at 1:00 AM | Brownstone Research (Ad)Trevi Therapeutics to Present at Multiple Healthcare and IPF Conferences in September 2026September 3, 2026 | quiverquant.comQTrevi Therapeutics to Participate in Upcoming September ConferencesSeptember 3, 2026 | globenewswire.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $27.08 Average Price Target from BrokeragesAugust 30, 2026 | americanbankingnews.comTrevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026August 26, 2026 | globenewswire.comTrevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough PlatformAugust 20, 2026 | seekingalpha.comSee More Headlines TRVI Stock Analysis - Frequently Asked Questions How have TRVI shares performed this year? Trevi Therapeutics' stock was trading at $12.52 at the beginning of the year. Since then, TRVI stock has increased by 37.9% and is now trading at $17.26. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics, Inc. (NASDAQ:TRVI) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.00. Read the conference call transcript. When did Trevi Therapeutics IPO? Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Trevi Therapeutics' major shareholders? Trevi Therapeutics' top institutional shareholders include BlackRock Inc. (7.86%), Wellington Management Group LLP (3.99%), Artia Global Partners LP (1.55%) and California State Teachers Retirement System (1.41%). Insiders that own company stock include David P Meeker, Thomas Sciascia, Jennifer L Good, Farrell Simon and Lisa Delfini. View institutional ownership trends. How do I buy shares of Trevi Therapeutics? Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC). Company Calendar Last Earnings8/06/2026Today9/08/202612th Annual Cantor Fitzgerald Global Healthcare Conference9/11/2026Morgan Stanley 24th Annual Global Healthcare Conference9/15/202610th Anniversary IPF Summit10/01/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (31m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TRVI's financial health is in the Green zone, according to TradeSmith. TRVI has been in this zone for over 31 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TRVI CIK1563880 Webwww.trevitherapeutics.com Phone(203) 304-2499FaxN/AEmployees20Year Founded2011Price Target and Rating Average Price Target for Trevi Therapeutics$27.08 High Price Target$40.00 Low Price Target$16.00 Potential Upside/Downside+56.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$42.76 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.59% Return on Assets-22.64% Debt Debt-to-Equity RatioN/A Current Ratio37.28 Quick Ratio37.28 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.43 per share Price / Book12.07Miscellaneous Outstanding Shares142,480,000Free Float120,549,000Market Cap$2.46 billion OptionableOptionable Beta1.04 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TRVI) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredForget SpaceX, Elon Is Now Powering the Next Hot IPOElon Musk is backing a new AI startup that's quietly growing faster than Tesla, SpaceX, and reportedly 23 time...Brownstone Research | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredElon's Terrifying Warning: America Is "1,000% Going Bankrupt"The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...American Hartford Gold | SponsoredBuffett’s “Green New Deal” (trigger warning!)Warren Buffett's largest stock bet ever now tops 29 billion dollars, dwarfing his historic positions in Coca-C...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
